Denali Therapeutics Inc.
DNLI
$24.20
-$0.72-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -6.48% | 6.07% | |||
| Gross Profit | 9.96% | -6.07% | |||
| SG&A Expenses | 8.27% | -15.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.88% | -0.01% | |||
| Operating Income | 5.51% | 0.01% | |||
| Income Before Tax | 0.70% | 0.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.70% | 0.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.70% | 0.08% | |||
| EBIT | 5.51% | 0.01% | |||
| EBITDA | 6.20% | -0.01% | |||
| EPS Basic | 1.05% | 6.06% | |||
| Normalized Basic EPS | 2.60% | 6.26% | |||
| EPS Diluted | 1.05% | 6.06% | |||
| Normalized Diluted EPS | 2.60% | 6.26% | |||
| Average Basic Shares Outstanding | 0.36% | 6.37% | |||
| Average Diluted Shares Outstanding | 0.36% | 6.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||